Jilin Aodong Pharmaceutical Group Co., Ltd. Share Price

Equities

000623

CNE000000719

Pharmaceuticals

End-of-day quote Shenzhen S.E. 03:30:00 20/05/2024 am IST 5-day change 1st Jan Change
15.03 CNY +0.20% Intraday chart for Jilin Aodong Pharmaceutical Group Co., Ltd. +0.27% -0.73%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 404.64Cr 56Cr 4.66TCr Sales 2025 * 469.03Cr 65Cr 5.4TCr Capitalization 1.8TCr 248.45Cr 21TCr
Net income 2024 * 232.9Cr 32Cr 2.68TCr Net income 2025 * 269.2Cr 37Cr 3.1TCr EV / Sales 2024 * 4.44 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 3.83 x
P/E ratio 2024 *
7.75 x
P/E ratio 2025 *
6.69 x
Employees 5,646
Yield 2024 *
-
Yield 2025 *
-
Free-Float 65.41%
More Fundamentals * Assessed data
Dynamic Chart
Jilin Aodong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Aodong Medicine's 2023 Profit Declines 18%; Revenue Up 20% MT
Jilin Aodong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Tranche Update on Jilin Aodong Pharmaceutical Group Co., Ltd.'s Equity Buyback Plan announced on September 21, 2023. CI
Jilin Aodong Pharmaceutical Group Co., Ltd.'s Equity Buyback announced on September 21, 2023, has closed with 9,015,780 shares, representing 0.8% for CNY 150 million. CI
Jilin Aodong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Chinese listed firms used endangered animal parts as ingredients -report RE
Three listed Chinese firms used endangered animal parts as ingredients- report RE
Tranche Update on Jilin Aodong Pharmaceutical Group Co., Ltd.'s Equity Buyback Plan announced on September 21, 2023. CI
Jilin Aodong Pharmaceutical Group Co., Ltd. announces an Equity Buyback for CNY 150 million worth of its shares. CI
Jilin Aodong Pharmaceutical Group Co., Ltd. authorizes a Buyback Plan. CI
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. cancelled the acquisition of Beijing Langyan Life Technology Holdings Co., Ltd. from a group of shareholders. CI
Jilin Aodong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Jilin Aodong Yanbian Pharmaceutical Co., Ltd. announced that it expects to receive CNY 200 million in funding from Jilin Aodong Pharmaceutical Group Co., Ltd. CI
Jilin Aodong Pharmaceutical Group Co., Ltd. Elects Liang Biming as Independent Director CI
More news
1 day+0.20%
1 week+0.27%
Current month+0.94%
1 month+1.83%
3 months-0.86%
6 months-8.58%
Current year-0.73%
More quotes
1 week
14.74
Extreme 14.74
15.16
1 month
14.61
Extreme 14.61
15.33
Current year
13.13
Extreme 13.13
15.66
1 year
13.13
Extreme 13.13
18.17
3 years
13.13
Extreme 13.13
19.90
5 years
13.13
Extreme 13.13
19.90
10 years
11.45
Extreme 11.4462
35.62
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 01/98/01
Director of Finance/CFO 47 01/04/01
Director of Finance/CFO 50 01/99/01
Members of the board TitleAgeSince
Chairman 71 01/93/01
Chief Executive Officer 61 01/98/01
Director/Board Member 52 06/08/06
More insiders
Date Price Change Volume
20/24/20 15.03 +0.20% 11,085,790
17/24/17 15 +1.15% 10,425,520
16/24/16 14.83 -0.13% 8,431,558
15/24/15 14.85 -1.39% 10,983,690
14/24/14 15.06 +0.47% 10,811,650

End-of-day quote Shenzhen S.E., May 20, 2024

More quotes
Jilin Aodong Pharmaceutical Group Co., Ltd. specializes in the manufacturing and marketing of pharmaceutical products. Besides, the group offers food products. Net sales break down by activity as follows: - sale of pharmaceutical products (89.4%); - sale of food products (6.8%); - other (3.8%). All sales are in China.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
15.03 CNY
Average target price
22.67 CNY
Spread / Average Target
+50.83%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 000623 Stock
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW